- Home
- RGC vs LEGN Comparison
RGC vs LEGN Comparison
Compare RGC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- LEGN
- Stock Information
- Founded
- RGC 2014
- LEGN 2014
- Country
- RGC Hong Kong
- LEGN United States
- Employees
- RGC N/A
- LEGN N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- LEGN Health Care
- Exchange
- RGC Nasdaq
- LEGN Nasdaq
- Market Cap
- RGC 6.6B
- LEGN 6.7B
- IPO Year
- RGC 2021
- LEGN 2020
- Fundamental
- Price
- RGC $14.70
- LEGN $33.11
- Analyst Decision
- RGC
- LEGN Strong Buy
- Analyst Count
- RGC 0
- LEGN 12
- Target Price
- RGC N/A
- LEGN $73.36
- AVG Volume (30 Days)
- RGC 278.7K
- LEGN 1.1M
- Earning Date
- RGC 10-24-2025
- LEGN 11-11-2025
- Dividend Yield
- RGC N/A
- LEGN N/A
- EPS Growth
- RGC N/A
- LEGN N/A
- EPS
- RGC N/A
- LEGN N/A
- Revenue
- RGC N/A
- LEGN $796,838,000.00
- Revenue This Year
- RGC N/A
- LEGN $70.75
- Revenue Next Year
- RGC N/A
- LEGN $52.47
- P/E Ratio
- RGC N/A
- LEGN N/A
- Revenue Growth
- RGC N/A
- LEGN 74.75
- 52 Week Low
- RGC $0.09
- LEGN $27.34
- 52 Week High
- RGC $83.60
- LEGN $52.31
- Technical
- Relative Strength Index (RSI)
- RGC 54.56
- LEGN 36.16
- Support Level
- RGC $13.06
- LEGN $33.20
- Resistance Level
- RGC $13.75
- LEGN $34.71
- Average True Range (ATR)
- RGC 1.14
- LEGN 1.22
- MACD
- RGC 0.20
- LEGN -0.09
- Stochastic Oscillator
- RGC 57.47
- LEGN 10.96
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.